Response by PD-L1 expression status in tumor types with ≥10 patients
| GC (n=54) | EC (n=54) | HCC (n=50) | OC (n=51) | NSCLC (n=49) | TNBC (n=21) | CRC* (n=21) | HNSCC (n=20) | UC (n=17) | CC (n=18) | RCC (n=16) | |
| Overall ORR (CR, PR) | |||||||||||
| % (95% CI) | 13.0 (5.37 to 24.90) | 11.1 (4.19 to 22.63) | 12.0 (4.53 to 24.31) | 9.8 (3.26 to 21.41) | 12.2 (4.63 to 24.77) | 0 (0 to 16.11) | 14.3 (3.05 to 36.34) | 15.0 (3.21 to 37.89) | 29.4 (10.31 to 55.96) | 0 (0 to 18.53) | 31.3 (11.02 to 58.66) |
| PD-L1+† | 23 | 33 | 26 | 21 | 16 | 14 | 6 | 5 | 9 | 7 | 6 |
| % (95% CI) | 17.4 (4.95 to 38.78) | 12.1 (3.40 to 28.20) | 23.1 (8.97 to 43.65) | 14.3 (3.05 to 36.34) | 18.8 (4.05 to 45.65) | 0 (0 to 23.16) | 33.3 (4.33 to 77.72) | 20.0 (0.51 to 71.64) | 33.3 (7.49 to 70.07) | 0 (0 to 40.96) | 33.3 (4.33 to 77.72) |
| PD-L1−†‡ | 22 | 16 | 19 | 23 | 21 | 5 | 12 | 12 | 7 | 5 | 9 |
| % (95% CI) | 4.5 (0.12 to 22.84) | 6.3 (0.16 to 30.23) | 0 (0 to 17.65) | 8.7 (1.07 to 28.04) | 9.5 (1.17 to 30.38) | 0 (0 to 52.18) | 8.3 (0.21 to 38.48) | 8.3 (0.21 to 38.48) | 14.3 (0.36 to 57.87) | 0 (0 to 52.18) | 33.3 (7.49 to 70.07) |
| PD-L1 unknown‡ | 9 | 5 | 5 | 7 | 12 | 2 | 3 | 3 | 1 | 6 | 1 |
| % (95% CI) | 22.2 (2.81 to 60.01) | 20.0 (0.51 to 71.64) | 0 (0 to 52.18) | 0 (0 to 40.96) | 8.3 (0.21 to 38.48) | 0 (0 to 84.19) | 0 (0 to 70.76) | 33.3 (0.84 to 90.57) | 100 (2.50 to 100.00) | 0 (0 to 45.93) | 0 (0 to 97.50) |
*Five patients with CRC were considered to have high microsatellite instability.
†PD-L1 expression positive was specific to indication (GC: TC ≥25% or IC ≥25%; EC: TC ≥25% or IC ≥25%; HCC: TC ≥1%; OC: TC ≥25% or IC ≥25%; NSCLC: TC ≥25%; TNBC: IC/TA ≥1%; CRC: TC ≥1%; HNSCC: TC ≥25%; UC: TC ≥25% or IC ≥25%; CC: TC ≥1%; RCC: IC/TA≥1%).
‡Percentages are calculated based on the total number of patients in each subcategory.
CC, cholangiocarcinoma; CR, complete response; CRC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; IC, immune cell; NSCLC, non-small cell lung cancer; OC, ovarian cancer; ORR, objective response rate; PD-1, programmed cell death-1; PD-L1, programmed cell death ligand-1; PR, partial response; RCC, renal cell carcinoma; TA, tumor area; TC, tumor cell; TNBC, triple-negative breast cancer; UC, urothelial carcinoma.